C4 Therapeutics Secures Roche DAC Partnership with $20M Upfront, $1B+ Milestones
C4 Therapeutics announced a new collaboration and license agreement with Roche to develop degrader-antibody conjugates (DACs) for oncology targets. The agreement includes an upfront payment of $20.0 million and potential milestone payments exceeding $1.0 billion. For the six months ended June 30, 2026, the company reported a net loss of $48.8 million, an improvement from $52.3 million in the prior year period. C4 Therapeutics also confirmed its cash, cash equivalents, and marketable securities of $300.4 million are sufficient to fund operations for at least the next twelve months.
Key Highlights
- Entered new collaboration with Roche for degrader-antibody conjugates (DACs).
- Received $20.0 million upfront payment from Roche.
- Eligible for over $1.0 billion in potential milestone payments from Roche.
- Net loss for six months ended June 30, 2026, was $(48.8) million.
- Net loss per share improved to $(0.38) for the six months.
- Cash, cash equivalents, and marketable securities totaled $300.4 million.
- Existing funds sufficient for at least the next 12 months of operations.
Price Impact
More from CCCC
C4 Therapeutics Presents Positive Biomarker Data for Cemsidomide in Multiple Myeloma Trials
C4 Therapeutics Q2 Net Loss $23.6M, EPS $0.18; Cemsidomide Trials On Track
C4 Therapeutics Stockholders Elect Directors, Approve Plan Amendment